EDSA
Edesa Biotech·NASDAQ
--
--(--)
--
--(--)
6.62 / 10
Outperform
Analyst coverage is limited but highly positive: one Strong Buy (100%). Fund‑flow rating is good (7.75), with overall inflow ratio ~0.493 and small‑cap inflows positive, while larger blocks show net outflows. Sentiment score 6.62 signals strong capital interest.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Yi ChenStrong Buy
Date2025-11-03
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for EDSA?
- EDSA holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.62/10 (Outperform).
